{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T14:48:36Z","timestamp":1773326916302,"version":"3.50.1"},"reference-count":152,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.clinbiochem.2026.111092","type":"journal-article","created":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T22:44:28Z","timestamp":1769985868000},"page":"111092","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Autoantibody testing in neuromuscular medicine: assay technologies, interpretation, and clinical utility"],"prefix":"10.1016","volume":"142","author":[{"given":"Tony","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Divyanshu","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinbiochem.2026.111092_b0005","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/B978-0-12-823912-4.00020-7","article-title":"Paraneoplastic neuropathies and peripheral nerve hyperexcitability disorders","volume":"200","author":"Shelly","year":"2024","journal-title":"Handb. Clin. Neurol."},{"issue":"4","key":"10.1016\/j.clinbiochem.2026.111092_b0010","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1212\/CON.0000000000001461","article-title":"Autoimmune neuromuscular disorders associated with neural antibodies","volume":"30","author":"Dubey","year":"2024","journal-title":"Continuum (minneap Minn)."},{"key":"10.1016\/j.clinbiochem.2026.111092_b0015","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420985323","article-title":"Paraneoplastic neurological syndromes: clinical presentations and management","volume":"14","author":"Devine","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"4","key":"10.1016\/j.clinbiochem.2026.111092_b0020","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209725","article-title":"Antibodies in autoimmune neuropathies: what to test, how to test, why to test","volume":"103","author":"Pascual-Goni","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.clinbiochem.2026.111092_b0025","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1495205","article-title":"Autoantibodies in neuromuscular disorders: a review of their utility in clinical practice","volume":"15","author":"Loser","year":"2024","journal-title":"Front. Neurol."},{"key":"10.1016\/j.clinbiochem.2026.111092_b0030","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/B978-0-444-63432-0.00023-2","article-title":"Autoimmune-mediated peripheral neuropathies and autoimmune pain","volume":"133","author":"Klein","year":"2016","journal-title":"Handb. Clin. Neurol."},{"issue":"6","key":"10.1016\/j.clinbiochem.2026.111092_b0035","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/BOR.0000000000000641","article-title":"The role of cancer-associated autoantibodies as biomarkers in paraneoplastic myositis syndrome","volume":"31","author":"Lu","year":"2019","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.clinbiochem.2026.111092_b0040","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.clim.2018.12.007","article-title":"A large screen for paraneoplastic neurological autoantibodies; diagnosis and predictive values","volume":"199","author":"Seluk","year":"2019","journal-title":"Clin. Immunol."},{"issue":"1\u20132","key":"10.1016\/j.clinbiochem.2026.111092_b0045","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0022-510X(01)00580-9","article-title":"Temporal profile of anti-ganglioside antibodies and their relation to clinical parameters and treatment in Guillain-Barre syndrome","volume":"190","author":"Press","year":"2001","journal-title":"J. Neurol. Sci."},{"issue":"20","key":"10.1016\/j.clinbiochem.2026.111092_b0050","first-page":"761","article-title":"Anti-GQ1b antibodies: usefulness of its detection for the diagnosis of Miller-Fisher syndrome","volume":"116","author":"Rojas-Garcia","year":"2001","journal-title":"Med. Clin. (Barc.)"},{"issue":"5","key":"10.1016\/j.clinbiochem.2026.111092_b0055","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1128\/IAI.67.5.2414-2420.1999","article-title":"Distinct immunoglobulin class and immunoglobulin G subclass patterns against ganglioside GQ1b in Miller Fisher syndrome following different types of infection","volume":"67","author":"Schwerer","year":"1999","journal-title":"Infect. Immun."},{"issue":"9","key":"10.1016\/j.clinbiochem.2026.111092_b0060","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/jamaneurol.2020.0781","article-title":"Monitoring clinical course and treatment response in chronic inflammatory demyelinating polyneuropathy during routine care: a review of clinical and laboratory assessment measures","volume":"77","author":"Allen","year":"2020","journal-title":"JAMA Neurol."},{"issue":"12","key":"10.1016\/j.clinbiochem.2026.111092_b0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114060","article-title":"Repeated acetylcholine receptor antibody-concentrations and association to clinical myasthenia gravis development","volume":"9","author":"Heldal","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.clinbiochem.2026.111092_b0070","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/trf.17766","article-title":"Autoantibody profiles in intravenous immunoglobulin preparations: a possible cause of mistaken autoimmunity diagnosis","volume":"64","author":"Miyamoto","year":"2024","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.clinbiochem.2026.111092_b0075","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001014","article-title":"Updated diagnostic criteria for paraneoplastic neurologic syndromes","volume":"8","author":"Graus","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"3","key":"10.1016\/j.clinbiochem.2026.111092_b0080","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031833","article-title":"The molecular executors of immune-mediated cytotoxicity","volume":"23","author":"Hay","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.clinbiochem.2026.111092_b0085","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/mus.26051","article-title":"Composite ganglioside autoantibodies and immune treatment response in MMN and MADSAM","volume":"57","author":"Martinez-Thompson","year":"2018","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.clinbiochem.2026.111092_b0090","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1212\/WNL.47.4.951","article-title":"The sensitivity and specificity of anti-GM1 antibody testing","volume":"47","author":"Taylor","year":"1996","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.clinbiochem.2026.111092_b0095","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1365-3083.2009.02338.x","article-title":"Structural difference in the complement activation site of human IgG1 and IgG3","volume":"70","author":"Michaelsen","year":"2009","journal-title":"Scand. J. Immunol."},{"issue":"2","key":"10.1016\/j.clinbiochem.2026.111092_b0100","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s12016-018-8679-y","article-title":"The immunologic paradoxes of IgG4-related disease","volume":"54","author":"Xiao","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"10.1016\/j.clinbiochem.2026.111092_b0105","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001116","article-title":"IgG4-Mediated Neurologic autoimmunities: understanding the pathogenicity of IgG4, ineffectiveness of IVIg, and long-lasting benefits of anti-b cell therapies","volume":"9","author":"Dalakas","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"10.1016\/j.clinbiochem.2026.111092_b0110","article-title":"The changing landscape of autoantibody testing in myasthenia gravis in the setting of novel drug treatments","volume":"133\u2013134","author":"Mousavi","year":"2024","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.clinbiochem.2026.111092_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2025.102594","article-title":"Pathogenic mechanisms of autoantibodies in neurological autoimmune diseases","volume":"95","author":"Fan","year":"2025","journal-title":"Curr. Opin. Immunol."},{"issue":"5","key":"10.1016\/j.clinbiochem.2026.111092_b0120","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/WCO.0000000000001107","article-title":"Autoimmune nodopathies, an emerging diagnostic category","volume":"35","author":"Martin-Aguilar","year":"2022","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.clinbiochem.2026.111092_b0125","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.3389\/fimmu.2020.01482","article-title":"The diagnostic value of onconeural antibodies depends on how they are tested","volume":"11","author":"Ruiz-Garcia","year":"2020","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.clinbiochem.2026.111092_b0130","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000701","article-title":"Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromes","volume":"7","author":"Dechelotte","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"10.1016\/j.clinbiochem.2026.111092_b0135","unstructured":"Dalmau J GF. Autoimmunity Against Proteins Associated with Voltage-Gated Potassium Channels. In: Autoimmune Encephalitis and Related Disorders of the Nervous System: Cambridge University Press; 2022."},{"key":"10.1016\/j.clinbiochem.2026.111092_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2025.578681","article-title":"N-type voltage-gated calcium channel antibody testing lacks diagnostic value in Lambert-Eaton myasthenic syndrome","volume":"406","author":"Arlt","year":"2025","journal-title":"J. Neuroimmunol."},{"issue":"24","key":"10.1016\/j.clinbiochem.2026.111092_b0145","doi-asserted-by":"crossref","first-page":"e2966","DOI":"10.1212\/WNL.0000000000012050","article-title":"Clinical utility of striational antibodies in paraneoplastic and myasthenia gravis paraneoplastic panels","volume":"96","author":"Shelly","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.clinbiochem.2026.111092_b0150","doi-asserted-by":"crossref","unstructured":"Triplett JD, Shelly S, Livne G, Milone M, Kassardjian CD, Liewluck T, et al. Diagnostic modelling and therapeutic monitoring of immune-mediated necrotizing myopathy: role of electrical myotonia. Brain Commun. 2020;2(2):fcaa191.","DOI":"10.1093\/braincomms\/fcaa191"},{"issue":"1\u20132","key":"10.1016\/j.clinbiochem.2026.111092_b0155","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jns.2013.04.015","article-title":"Observations on chronic inflammatory demyelinating polyneuropathy: a plea for a rigorous approach to diagnosis and treatment","volume":"330","author":"Cornblath","year":"2013","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.clinbiochem.2026.111092_b0160","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/mus.25997","article-title":"Electrodiagnostic errors contribute to chronic inflammatory demyelinating polyneuropathy misdiagnosis","volume":"57","author":"Allen","year":"2018","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.clinbiochem.2026.111092_b0165","doi-asserted-by":"crossref","DOI":"10.1111\/jns.12682","article-title":"Distinguishing chronic inflammatory demyelinating polyneuropathy from mimic disorders: the role of statistical modeling","volume":"30","author":"Swart","year":"2025","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.clinbiochem.2026.111092_b0170","doi-asserted-by":"crossref","DOI":"10.1177\/1756285617746640","article-title":"Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies","volume":"11","author":"Dalakas","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"9","key":"10.1016\/j.clinbiochem.2026.111092_b0175","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1212\/WNL.0b013e3181b59a80","article-title":"Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy","volume":"73","author":"Kuijf","year":"2009","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.clinbiochem.2026.111092_b0180","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000210000","article-title":"Optimizing anti-myelin-associated glycoprotein and IgM-gammopathy testing for neuropathy treatment evaluation","volume":"103","author":"Klein","year":"2024","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.clinbiochem.2026.111092_b0185","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001109","article-title":"Decrease in serum anti-MAG autoantibodies is associated with therapy response in patients with anti-mag neuropathy: retrospective study","volume":"9","author":"Hanggi","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"4","key":"10.1016\/j.clinbiochem.2026.111092_b0190","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000771","article-title":"Contactin-1 autoimmunity: serologic, neurologic, and pathologic correlates","volume":"7","author":"Dubey","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"10.1016\/j.clinbiochem.2026.111092_b0195","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.expneurol.2016.10.006","article-title":"Complement deposition induced by binding of anti-contactin-1 auto-antibodies is modified by immunoglobulins","volume":"287","author":"Appeltshauser","year":"2017","journal-title":"Exp. Neurol."},{"issue":"4","key":"10.1016\/j.clinbiochem.2026.111092_b0200","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/brain\/awab014","article-title":"Antibodies to the Caspr1\/contactin-1 complex in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"144","author":"Pascual-Goni","year":"2021","journal-title":"Brain"},{"issue":"10","key":"10.1016\/j.clinbiochem.2026.111092_b0205","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1136\/jnnp-2021-326343","article-title":"IgG pan-neurofascin antibodies identify a severe yet treatable neuropathy with a high mortality","volume":"92","author":"Fehmi","year":"2021","journal-title":"J Neurol Neurosur Ps."},{"issue":"1","key":"10.1016\/j.clinbiochem.2026.111092_b0210","doi-asserted-by":"crossref","DOI":"10.1111\/jns.70000","article-title":"Inter-laboratory validation of nodal\/paranodal antibody testing","volume":"30","author":"Lleixa","year":"2025","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"12","key":"10.1016\/j.clinbiochem.2026.111092_b0215","doi-asserted-by":"crossref","first-page":"3646","DOI":"10.1111\/ene.16073","article-title":"European academy of neurology\/peripheral nerve society guideline on diagnosis and treatment of guillain-barre syndrome","volume":"30","author":"van Doorn","year":"2023","journal-title":"Eur. J. Neurol."},{"issue":"Suppl 2","key":"10.1016\/j.clinbiochem.2026.111092_b0220","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1086\/513799","article-title":"Mechanisms of action of anti-GM1 and anti-GQ1b ganglioside antibodies in Guillain-Barre syndrome","volume":"176","author":"Willison","year":"1997","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.clinbiochem.2026.111092_b0225","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/1531-8249(199902)45:2<168::AID-ANA6>3.0.CO;2-6","article-title":"Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barre syndrome","volume":"45","author":"Ho","year":"1999","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.clinbiochem.2026.111092_b0230","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1136\/jnnp-2019-321532","article-title":"Multifocal motor neuropathy: controversies and priorities","volume":"91","author":"Yeh","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.clinbiochem.2026.111092_b0235","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrneurol.2011.175","article-title":"Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies","volume":"8","author":"Vlam","year":"2011","journal-title":"Nat. Rev. Neurol."},{"issue":"14","key":"10.1016\/j.clinbiochem.2026.111092_b0240","doi-asserted-by":"crossref","first-page":"e1392","DOI":"10.1212\/WNL.0000000000012618","article-title":"Pure motor onset and igm-gammopathy occurrence in multifocal acquired demyelinating sensory and motor neuropathy","volume":"97","author":"Beecher","year":"2021","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.clinbiochem.2026.111092_b0245","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1136\/jnnp-2012-302824","article-title":"Bickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome","volume":"84","author":"Shahrizaila","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.clinbiochem.2026.111092_b0250","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/jnnp-2013-305397","article-title":"Pharyngeal-cervical-brachial variant of Guillain-Barre syndrome","volume":"85","author":"Wakerley","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.clinbiochem.2026.111092_b0255","unstructured":"Go S, Sato C. Thin-layer chromatography-immunostaining method and enzyme-linked immunosorbent assay for detection of gangliosides by specific antibodies. In: Nishihara S, Angata K, Aoki-Kinoshita KF, Hirabayashi J, editors. Glycoscience Protocols (GlycoPODv2). Saitama (JP)2021."},{"key":"10.1016\/j.clinbiochem.2026.111092_b0260","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/978-1-4939-7180-0_14","article-title":"Detection of naturally occurring human antibodies against gangliosides by ELISA","volume":"1643","author":"Hernandez","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.clinbiochem.2026.111092_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.116576","article-title":"Antiganglioside antibodies in neurological diseases","volume":"408","author":"Wanleenuwat","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.clinbiochem.2026.111092_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2024.122903","article-title":"Evaluating yield and utilization of ganglioside antibody testing in clinical practice","volume":"457","author":"Li","year":"2024","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.clinbiochem.2026.111092_b0275","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/630602","article-title":"Cell-mediated immune responses in paraneoplastic neurological syndromes","volume":"2013","author":"Zaborowski","year":"2013","journal-title":"Clin. Dev. Immunol."},{"issue":"3","key":"10.1016\/j.clinbiochem.2026.111092_b0280","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1001\/archneurol.2009.336","article-title":"Positron emission tomography-computed tomography in paraneoplastic neurologic disorders: systematic analysis and review","volume":"67","author":"McKeon","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.clinbiochem.2026.111092_b0285","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.729075","article-title":"CRMP5 antibodies-diagnostic challenges","volume":"12","author":"Totland","year":"2021","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2026.111092_b0290","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/jnnp-2019-321849","article-title":"Clinical characterisation of sensory neuropathy with anti-FGFR3 autoantibodies","volume":"91","author":"Tholance","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.clinbiochem.2026.111092_b0295","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/mus.23256","article-title":"Clinical and laboratory features of neuropathies with serum IgM binding to TS-HDS","volume":"45","author":"Pestronk","year":"2012","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.clinbiochem.2026.111092_b0300","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001032","article-title":"Argonaute autoantibodies as biomarkers in autoimmune neurologic diseases","volume":"8","author":"Do","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"5","key":"10.1016\/j.clinbiochem.2026.111092_b0305","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001028","article-title":"Antiplexin D1 antibodies relate to small fiber neuropathy and induce neuropathic pain in animals","volume":"8","author":"Fujii","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"10.1016\/j.clinbiochem.2026.111092_b0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102403","article-title":"A comprehensive analysis of the clinical characteristics and laboratory features in 179 patients with autoimmune autonomic ganglionopathy","volume":"108","author":"Nakane","year":"2020","journal-title":"J. Autoimmun."},{"issue":"10","key":"10.1016\/j.clinbiochem.2026.111092_b0315","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.mayocp.2018.05.033","article-title":"Ganglionic antibody level as a predictor of severity of autonomic failure","volume":"93","author":"Cutsforth-Gregory","year":"2018","journal-title":"Mayo Clin. Proc."},{"issue":"6","key":"10.1016\/j.clinbiochem.2026.111092_b0320","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/archneurol.2009.78","article-title":"Ganglionic acetylcholine receptor autoantibody: oncological, neurological, and serological accompaniments","volume":"66","author":"McKeon","year":"2009","journal-title":"Arch. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.clinbiochem.2026.111092_b0325","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.autneu.2008.09.005","article-title":"Autonomic ganglia, acetylcholine receptor antibodies, and autoimmune ganglionopathy","volume":"146","author":"Vernino","year":"2009","journal-title":"Auton. Neurosci."},{"issue":"3","key":"10.1016\/j.clinbiochem.2026.111092_b0330","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001162","article-title":"Novel cell-based assay for alpha-3 nicotinic receptor antibodies detects antibodies exclusively in autoimmune autonomic ganglionopathy","volume":"9","author":"Karagiorgou","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"2","key":"10.1016\/j.clinbiochem.2026.111092_b0335","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/ana.23577","article-title":"Morvan syndrome: clinical and serological observations in 29 cases","volume":"72","author":"Irani","year":"2012","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.clinbiochem.2026.111092_b0340","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/mus.25371","article-title":"Clinical-pathologic correlations in voltage-gated Kv1 potassium channel complex-subtyped autoimmune painful polyneuropathy","volume":"55","author":"Lahoria","year":"2017","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.clinbiochem.2026.111092_b0345","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ana.24979","article-title":"Expanded phenotypes and outcomes among 256 LGI1\/CASPR2-IgG-positive patients","volume":"82","author":"Gadoth","year":"2017","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.clinbiochem.2026.111092_b0350","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/WCO.0000000000001104","article-title":"Autoimmune neuromyotonia","volume":"35","author":"Comperat","year":"2022","journal-title":"Curr. Opin. Neurol."},{"issue":"5","key":"10.1016\/j.clinbiochem.2026.111092_b0355","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1097\/WCO.0000000000000963","article-title":"Neuromuscular hyperexcitability syndromes","volume":"34","author":"De Wel","year":"2021","journal-title":"Curr. Opin. Neurol."},{"issue":"22","key":"10.1016\/j.clinbiochem.2026.111092_b0360","doi-asserted-by":"crossref","first-page":"e3002","DOI":"10.1212\/WNL.0000000000010910","article-title":"Improving accuracy of myasthenia gravis autoantibody testing by reflex algorithm","volume":"95","author":"Shelly","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.clinbiochem.2026.111092_b0365","article-title":"Thymoma in myasthenia gravis: from diagnosis to treatment","volume":"2011","author":"Romi","year":"2011","journal-title":"Autoimmune Dis."},{"issue":"9","key":"10.1016\/j.clinbiochem.2026.111092_b0370","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213498","article-title":"Risk of false acetylcholine receptor autoantibody positivity by radioimmunoprecipitation assay in clinical practice","volume":"104","author":"Zara","year":"2025","journal-title":"Neurology"},{"issue":"Pt 4","key":"10.1016\/j.clinbiochem.2026.111092_b0375","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/brain\/aws025","article-title":"Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice","volume":"135","author":"Klooster","year":"2012","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.clinbiochem.2026.111092_b0380","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve"},{"issue":"7","key":"10.1016\/j.clinbiochem.2026.111092_b0385","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.nmd.2006.05.006","article-title":"A systematic review of diagnostic studies in myasthenia gravis","volume":"16","author":"Benatar","year":"2006","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.clinbiochem.2026.111092_b0390","article-title":"A multicentre, prospective, double-blind study comparing the accuracy of autoantibody diagnostic assays in myasthenia gravis: the SCREAM study","volume":"38","author":"Li","year":"2023","journal-title":"Lancet Reg Health West Pac."},{"issue":"1","key":"10.1016\/j.clinbiochem.2026.111092_b0395","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200038","article-title":"Comparison of fixed and live cell-based assay for the detection of achr and musk antibodies in myasthenia gravis","volume":"10","author":"Spagni","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"Pt 7","key":"10.1016\/j.clinbiochem.2026.111092_b0400","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis","volume":"131","author":"Leite","year":"2008","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.clinbiochem.2026.111092_b0405","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/archneurol.2012.437","article-title":"Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis","volume":"69","author":"Jacob","year":"2012","journal-title":"Arch. Neurol."},{"issue":"6","key":"10.1016\/j.clinbiochem.2026.111092_b0410","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/jamaneurol.2015.0203","article-title":"Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis","volume":"72","author":"Rodriguez Cruz","year":"2015","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.clinbiochem.2026.111092_b0415","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193723","article-title":"Myasthenia gravis seronegative for acetylcholine receptor antibodies in South Korea: autoantibody profiles and clinical features","volume":"13","author":"Park","year":"2018","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.clinbiochem.2026.111092_b0420","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/jnnp-2022-329284","article-title":"Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis","volume":"93","author":"Damato","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.clinbiochem.2026.111092_b0425","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","article-title":"A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis","volume":"52","author":"Zisimopoulou","year":"2014","journal-title":"J. Autoimmun."},{"issue":"5","key":"10.1016\/j.clinbiochem.2026.111092_b0430","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s004150050604","article-title":"Muscle autoantibodies in subgroups of myasthenia gravis patients","volume":"247","author":"Romi","year":"2000","journal-title":"J. Neurol."},{"key":"10.1016\/j.clinbiochem.2026.111092_b0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2022.577895","article-title":"LRP4-IgG service line testing in seronegative myasthenia gravis and controls","volume":"368","author":"Klein","year":"2022","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2026.111092_b0440","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0022-510X(96)05303-8","article-title":"Incidence of serum anti-P\/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome","volume":"147","author":"Motomura","year":"1997","journal-title":"J. Neurol. Sci."},{"issue":"22","key":"10.1016\/j.clinbiochem.2026.111092_b0445","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJM199506013322203","article-title":"Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes","volume":"332","author":"Lennon","year":"1995","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.clinbiochem.2026.111092_b0450","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1200\/JCO.2008.20.6169","article-title":"SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival","volume":"27","author":"Titulaer","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.clinbiochem.2026.111092_b0455","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.mayocp.2016.12.025","article-title":"Diagnosis and management of immune-mediated myopathies","volume":"92","author":"Milone","year":"2017","journal-title":"Mayo Clin. Proc."},{"issue":"3","key":"10.1016\/j.clinbiochem.2026.111092_b0460","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/25785826.2018.1531188","article-title":"Clinical significance of myositis-specific autoantibodies","volume":"41","author":"Nakashima","year":"2018","journal-title":"Immunol. Med."},{"issue":"1","key":"10.1016\/j.clinbiochem.2026.111092_b0465","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"19","key":"10.1016\/j.clinbiochem.2026.111092_b0470","article-title":"Detection of myositis autoantibodies by multi-analytic immunoassays in a large multicenter cohort of patients with definite idiopathic inflammatory myopathies","volume":"13","author":"Ghirardello","year":"2023","journal-title":"Diagnostics (basel)"},{"issue":"4\u20135","key":"10.1016\/j.clinbiochem.2026.111092_b0475","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.autrev.2014.01.022","article-title":"Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review","volume":"13","author":"Mahler","year":"2014","journal-title":"Autoimmun. Rev."},{"issue":"6","key":"10.1016\/j.clinbiochem.2026.111092_b0480","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/rheumatology\/kep078","article-title":"Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression","volume":"48","author":"Gunawardena","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinbiochem.2026.111092_b0485","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/OARRR.S231195","article-title":"Myositis specific autoantibodies: a clinical perspective","volume":"12","author":"Alenzi","year":"2020","journal-title":"Open Access Rheumatol."},{"issue":"10","key":"10.1016\/j.clinbiochem.2026.111092_b0490","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/art.1780381006","article-title":"The major dermatomyositis-specific Mi-2 autoantigen is a presumed helicase involved in transcriptional activation","volume":"38","author":"Seelig","year":"1995","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clinbiochem.2026.111092_b0495","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12948-018-0084-9","article-title":"Bench to bedside review of myositis autoantibodies","volume":"16","author":"Palterer","year":"2018","journal-title":"Clin Mol Allergy."},{"issue":"2","key":"10.1016\/j.clinbiochem.2026.111092_b0500","doi-asserted-by":"crossref","first-page":"R48","DOI":"10.1186\/ar4207","article-title":"Implications in the difference of anti-Mi-2 and -p155\/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara","volume":"15","author":"Petri","year":"2013","journal-title":"Arthritis Res. Ther."},{"issue":"19","key":"10.1016\/j.clinbiochem.2026.111092_b0505","doi-asserted-by":"crossref","first-page":"e1768","DOI":"10.1212\/WNL.0000000000008443","article-title":"More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodies","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.clinbiochem.2026.111092_b0510","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/art.24621","article-title":"RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease","volume":"60","author":"Sato","year":"2009","journal-title":"Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.clinbiochem.2026.111092_b0515","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/acr.21985","article-title":"Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis","volume":"65","author":"Chen","year":"2013","journal-title":"Arthritis Care Res (hoboken)."},{"issue":"1","key":"10.1016\/j.clinbiochem.2026.111092_b0520","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2010.09.016","article-title":"The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study","volume":"65","author":"Fiorentino","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"10.1016\/j.clinbiochem.2026.111092_b0525","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/archdermatol.2011.52","article-title":"Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study","volume":"147","author":"Hamaguchi","year":"2011","journal-title":"Arch. Dermatol."},{"issue":"10","key":"10.1016\/j.clinbiochem.2026.111092_b0530","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1002\/acr.21728","article-title":"Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody","volume":"64","author":"Cao","year":"2012","journal-title":"Arthritis Care Res (hoboken)."},{"issue":"5","key":"10.1016\/j.clinbiochem.2026.111092_b0535","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/annrheumdis-2011-200697","article-title":"Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy","volume":"71","author":"Ichimura","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.clinbiochem.2026.111092_b0540","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\u03b3","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum-Us."},{"issue":"2","key":"10.1016\/j.clinbiochem.2026.111092_b0545","doi-asserted-by":"crossref","first-page":"R97","DOI":"10.1186\/ar3822","article-title":"Anti-MJ\/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis\/dermatomyositis","volume":"14","author":"Ceribelli","year":"2012","journal-title":"Arthritis Res. Ther."},{"issue":"4","key":"10.1016\/j.clinbiochem.2026.111092_b0550","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3109\/08916934.2012.755958","article-title":"Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients","volume":"46","author":"Muro","year":"2013","journal-title":"Autoimmunity"},{"issue":"8","key":"10.1016\/j.clinbiochem.2026.111092_b0555","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1007\/s10067-019-04562-w","article-title":"Diffuse pruritic erythema as a clinical manifestation in anti-SAE antibody-associated dermatomyositis: a case report and literature review","volume":"38","author":"Jia","year":"2019","journal-title":"Clin. Rheumatol."},{"issue":"2","key":"10.1016\/j.clinbiochem.2026.111092_b0560","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s12016-022-08922-4","article-title":"Autoantibody markers of increased risk of malignancy in patients with dermatomyositis","volume":"63","author":"Marzecka","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"10.1016\/j.clinbiochem.2026.111092_b0565","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jaad.2014.12.009","article-title":"Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1gamma antibodies in adults with dermatomyositis","volume":"72","author":"Fiorentino","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"issue":"5","key":"10.1016\/j.clinbiochem.2026.111092_b0570","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11926-018-0733-5","article-title":"Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies","volume":"20","author":"Wolstencroft","year":"2018","journal-title":"Curr. Rheumatol. Rep."},{"issue":"9","key":"10.1016\/j.clinbiochem.2026.111092_b0575","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/jamaneurol.2015.1207","article-title":"Clinical features and treatment outcomes of necrotizing autoimmune myopathy","volume":"72","author":"Kassardjian","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.clinbiochem.2026.111092_b0580","doi-asserted-by":"crossref","unstructured":"Allenbach Y, Mammen AL, Benveniste O, Stenzel W, Immune-Mediated Necrotizing Myopathies Working G. 224th ENMC International Workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016. Neuromuscul Disord. 2018;28(1):87-99.","DOI":"10.1016\/j.nmd.2017.09.016"},{"issue":"10","key":"10.1016\/j.clinbiochem.2026.111092_b0585","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/jnnp-2016-313166","article-title":"Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy","volume":"87","author":"Watanabe","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.clinbiochem.2026.111092_b0590","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1212\/WNL.41.6.936","article-title":"Necrotizing myopathy with pipestem capillaries, microvascular deposition of the complement membrane attack complex (MAC), and minimal cellular infiltration","volume":"41","author":"Emslie-Smith","year":"1991","journal-title":"Neurology"},{"issue":"Pt 8","key":"10.1016\/j.clinbiochem.2026.111092_b0595","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1093\/brain\/aww054","article-title":"High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody","volume":"139","author":"Allenbach","year":"2016","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.clinbiochem.2026.111092_b0600","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/rheumatology\/keac144","article-title":"Cancer and immune-mediated necrotizing myopathy: a longitudinal referral case-controlled outcomes evaluation","volume":"62","author":"Shelly","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.clinbiochem.2026.111092_b0605","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMra1515161","article-title":"Statin-associated autoimmune myopathy","volume":"374","author":"Mammen","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.clinbiochem.2026.111092_b0610","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3233\/JND-170282","article-title":"Anti-HMGCR myopathy","volume":"5","author":"Mohassel","year":"2018","journal-title":"J Neuromuscul Dis."},{"issue":"4","key":"10.1016\/j.clinbiochem.2026.111092_b0615","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/jnnp.73.4.420","article-title":"Myopathy with antibodies to the signal recognition particle: clinical and pathological features","volume":"73","author":"Miller","year":"2002","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"9","key":"10.1016\/j.clinbiochem.2026.111092_b0620","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/art.1780330908","article-title":"Antibody to signal recognition particle in polymyositis","volume":"33","author":"Targoff","year":"1990","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.clinbiochem.2026.111092_b0625","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/acr.22920","article-title":"Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle","volume":"69","author":"Pinal-Fernandez","year":"2017","journal-title":"Arthritis Care Res (hoboken)."},{"issue":"35","key":"10.1016\/j.clinbiochem.2026.111092_b0630","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000011858","article-title":"Proposed cut-off for reactivity of anti-HMGCR and anti-SRP antibodies in patients statin-exposed and statin-unexposed","volume":"97","author":"Carvalho","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clinbiochem.2026.111092_b0635","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cca.2017.07.011","article-title":"Detection of autoantibodies to 3-hydroxy-3-methylglutaryl-coenzyme a reductase by ELISA in a reference laboratory setting","volume":"472","author":"Jaskowski","year":"2017","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.clinbiochem.2026.111092_b0640","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/405956","article-title":"Analysis of autoantibodies to 3-hydroxy-3-methylglutaryl-coenzyme a reductase using different technologies","volume":"2014","author":"Musset","year":"2014","journal-title":"J. Immunol. Res."},{"issue":"1","key":"10.1016\/j.clinbiochem.2026.111092_b0645","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s12026-016-8867-x","article-title":"Anti-HMGCR antibodies demonstrate high diagnostic value in the diagnosis of immune-mediated necrotizing myopathy following statin exposure","volume":"65","author":"Shovman","year":"2017","journal-title":"Immunol. Res."},{"issue":"1","key":"10.1016\/j.clinbiochem.2026.111092_b0650","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3109\/08923973.2015.1077461","article-title":"Detection of autoantibodies using chemiluminescence technologies","volume":"38","author":"Mahler","year":"2016","journal-title":"Immunopharmacol. Immunotoxicol."},{"issue":"6","key":"10.1016\/j.clinbiochem.2026.111092_b0655","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.pathol.2025.02.010","article-title":"Anti-HMGCR antibodies can be accurately detected by indirect immunofluorescence on HEp-2000 substrate","volume":"57","author":"Anderson","year":"2025","journal-title":"Pathology"},{"issue":"3","key":"10.1016\/j.clinbiochem.2026.111092_b0660","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s12026-015-8774-6","article-title":"Heterogeneous clinical spectrum of anti-SRP myositis and importance of the methods of detection of anti-SRP autoantibodies: a multicentric study","volume":"64","author":"Picard","year":"2016","journal-title":"Immunol. Res."},{"issue":"1","key":"10.1016\/j.clinbiochem.2026.111092_b0665","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/acr.22600","article-title":"Cytosolic 5'-nucleotidase 1a as a target of circulating autoantibodies in autoimmune diseases","volume":"68","author":"Lloyd","year":"2016","journal-title":"Arthritis Care Res. (hoboken)."},{"key":"10.1016\/j.clinbiochem.2026.111092_b0670","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3389\/fimmu.2019.00745","article-title":"Anti-NT5c1A autoantibodies as biomarkers in inclusion body myositis","volume":"10","author":"Amlani","year":"2019","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.clinbiochem.2026.111092_b0675","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/annrheumdis-2014-206691","article-title":"Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases","volume":"75","author":"Herbert","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"Pt 5","key":"10.1016\/j.clinbiochem.2026.111092_b0680","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/brain\/aww024","article-title":"Association of inclusion body myositis with T cell large granular lymphocytic leukaemia","volume":"139","author":"Greenberg","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.clinbiochem.2026.111092_b0685","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1153789","article-title":"Uncovering the significance of expanded CD8(+) large granular lymphocytes in inclusion body myositis: Insights into T cell phenotype and functional alterations, and disease severity","volume":"14","author":"McLeish","year":"2023","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.clinbiochem.2026.111092_b0690","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/BOR.0000000000000536","article-title":"The clinico-serological spectrum of overlap myositis","volume":"30","author":"Fredi","year":"2018","journal-title":"Curr. Opin. Rheumatol."},{"issue":"6","key":"10.1016\/j.clinbiochem.2026.111092_b0695","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/art.42813","article-title":"Myositis-associated autoantibodies in patients with juvenile myositis are associated with refractory disease and mortality","volume":"76","author":"Sherman","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.clinbiochem.2026.111092_b0700","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","article-title":"Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients","volume":"101","author":"Betteridge","year":"2019","journal-title":"J. Autoimmun."},{"issue":"9","key":"10.1016\/j.clinbiochem.2026.111092_b0705","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.autrev.2014.03.004","article-title":"The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome","volume":"13","author":"Lega","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.clinbiochem.2026.111092_b0710","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3389\/fimmu.2015.00412","article-title":"Report of the first international consensus on standardized nomenclature of antinuclear antibody HEp-2 cell patterns 2014-2015","volume":"6","author":"Chan","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clinbiochem.2026.111092_b0715","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00331","article-title":"Clinical usefulness of autoantibodies in idiopathic inflammatory myositis","volume":"6","author":"Garc\u00eda-De La Torre","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clinbiochem.2026.111092_b0720","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2016.02.017","article-title":"Testing for myositis specific autoantibodies: comparison between line blot and immunoprecipitation assays in 57 myositis sera","volume":"433","author":"Cavazzana","year":"2016","journal-title":"J. Immunol. Methods"},{"issue":"1","key":"10.1016\/j.clinbiochem.2026.111092_b0725","first-page":"1","article-title":"Autoantibodies to extractable nuclear antigens: making detection and interpretation more meaningful","volume":"9","author":"Phan","year":"2002","journal-title":"Clin. Diagn. Lab. Immunol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2026.111092_b0730","first-page":"176","article-title":"Autoantibody testing in patients with myositis: clinical accuracy of a multiparametric line immunoassay","volume":"35","author":"Ghirardello","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2026.111092_b0735","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.autrev.2009.03.005","article-title":"Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies","volume":"9","author":"Ronnelid","year":"2009","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.clinbiochem.2026.111092_b0740","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2019.112661","article-title":"Evaluation of a novel particle-based assay for detection of autoantibodies in idiopathic inflammatory myopathies","volume":"474","author":"Cavazzana","year":"2019","journal-title":"J. Immunol. Methods"},{"issue":"12","key":"10.1016\/j.clinbiochem.2026.111092_b0745","article-title":"Profiling of myositis specific antibodies and composite scores as an aid in the differential diagnosis of autoimmune myopathies","volume":"11","author":"Mahler","year":"2021","journal-title":"Diagnostics (basel)"},{"issue":"7","key":"10.1016\/j.clinbiochem.2026.111092_b0750","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1212\/WNL.52.7.1453","article-title":"Phenotypic variability in rippling muscle disease","volume":"52","author":"Vorgerd","year":"1999","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.clinbiochem.2026.111092_b0755","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1001\/jamaneurol.2022.1357","article-title":"Identification of caveolae-associated protein 4 autoantibodies as a biomarker of immune-mediated rippling muscle disease in adults","volume":"79","author":"Dubey","year":"2022","journal-title":"JAMA Neurol."},{"issue":"4","key":"10.1016\/j.clinbiochem.2026.111092_b0760","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/acn3.70012","article-title":"High-throughput immunoassays for Cavin-4 IgG: a diagnostic tool for immune-mediated rippling muscle disease","volume":"12","author":"LaFrance-Corey","year":"2025","journal-title":"Ann. Clin. Transl. Neurol."}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912026000202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912026000202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:08:39Z","timestamp":1773277719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912026000202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":152,"alternative-id":["S0009912026000202"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2026.111092","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoantibody testing in neuromuscular medicine: assay technologies, interpretation, and clinical utility","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2026.111092","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111092"}}